Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-9632P in Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT05435729Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DSP-9632P in levodopa-induced dyskinesia (LID) (4 arms), sponsored by Sumitomo Pharma. Primary endpoints: Binding potential of 11C-raclopride and Dopamine D2 receptor occupancy at 1 day and Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to treatment discontinuation at 7 days. Started May 2022; status: completed.
02
Drugs
DSP-9632P
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT05435729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435729.